> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts TG Theraputics NDA for Lymphoma
- URL: https://www.fdaweb.com/fda-accepts-tg-theraputics-nda-for-lymphoma/
- Published: 2020-08-13T12:00:00.000Z
- Updated: 2026-09-14T16:24:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147430

FDA has accepted a TG Therapeutics NDA for umbralisib, a once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon for treating patients with previously treated marginal zone lymphoma who have received at least one prior anti-CD20 based regimen and patients with follicular lymphoma who have received at least two prior systemic therapies. The agency has set a 2/15/2021 user fee review action target date. FDA previously granted umbralisib a breakthrough therapy designation and an orphan drug designation for marginal zone lymphoma and an orphan drug designation for follicular lymphoma.

The submission was based on data from the UNITY-NHL Phase 2b trial evaluating patients with relapsed/refractory marginal zone lymphoma or follicular lymphoma. The company says that each cohort met its primary endpoint of 40-50% overall response rate, as confirmed by an independent review committee.